Identification, Synthesis and Biological Activity of Alkyl-guanidine Oligomers As Potent Antibacterial Agents

Overview

Journal Sci Rep

Specialty Science

Date 2017 Aug 17

PMID 28811659

Citations 11

Authors

C Zamperini

G Maccari

D Deodato

C Pasero

I DAgostino

F Orofino

F De Luca

E Dreassi

J D Docquier

M Botta

Affiliations

Soon will be listed here.

Abstract

In the last two decades, the repertoire of clinically effective antibacterials is shrinking due to the rapidly increasing of multi-drug-resistant pathogenic bacteria. New chemical classes with innovative mode of action are required to prevent a return to the pre-antibiotic era. We have recently reported the identification of a series of linear guanidine derivatives and their antibacterial properties. A batch of a promising candidate for optimization studies (compound 1) turned out to be a mixture containing two unknown species with a better biological activity than the pure compound. This serendipitous discovery led us to investigate the chemical nature of the unknown components of the mixture. Through MS analysis coupled with design and synthesis we found that the components were spontaneously generated oligomers of the original compound. Preliminary biological evaluations eventually confirmed the broad-spectrum antibacterial activity of this new family of molecules. Interestingly the symmetric dimeric derivative (2) exhibited the best profile and it was selected as lead compound for further studies.

Citing Articles

Guanethidine Enhances the Antibacterial Activity of Rifampicin Against Multidrug-Resistant Bacteria.

Zhao X, Zhang Z, Liu L, Wang D, Zhang X, Zhao L Microorganisms. 2024; 12(11).

PMID: 39597596 PMC: 11596751. DOI: 10.3390/microorganisms12112207.

Azo derivatives of monoterpenes as anti- agents: from synthesis to structure-based target investigation.

Melfi F, Fantacuzzi M, Carradori S, DAgostino I, Ammazzalorso A, Mencarelli N RSC Med Chem. 2024; .

PMID: 39493229 PMC: 11526209. DOI: 10.1039/d4md00511b.

A New Guanidine-Core Small-Molecule Compound as a Potential Antimicrobial Agent against Resistant Bacterial Strains.

Morata-Moreno N, Perez-Tanoira R, Del Campo-Balguerias A, Carrillo-Hermosilla F, Hernando-Gozalo M, Rescalvo-Casas C Antibiotics (Basel). 2024; 13(7).

PMID: 39061291 PMC: 11274109. DOI: 10.3390/antibiotics13070609.

Carbon Nanodisks Decorated with Guanidinylated Hyperbranched Polyethyleneimine Derivatives as Efficient Antibacterial Agents.

Lyra K, Tournis I, Subrati M, Spyrou K, Papavasiliou A, Athanasekou C Nanomaterials (Basel). 2024; 14(8).

PMID: 38668171 PMC: 11054016. DOI: 10.3390/nano14080677.

Synthesis, biological evaluation and in-silico ADME studies of novel series of thiazolidin-2,4-dione derivatives as antimicrobial, antioxidant and anticancer agents.

Kumar H, Kumar D, Kumar P, Thareja S, Marwaha M, Navik U BMC Chem. 2022; 16(1):68.

PMID: 36109764 PMC: 9479363. DOI: 10.1186/s13065-022-00861-7.

References

Wang B, Pachaiyappan B, Gruber J, Schmidt M, Zhang Y, Woster P . Antibacterial Diamines Targeting Bacterial Membranes. J Med Chem. 2016; 59(7):3140-51. PMC: 5927580. DOI: 10.1021/acs.jmedchem.5b01912. View

Silver L . Challenges of antibacterial discovery. Clin Microbiol Rev. 2011; 24(1):71-109. PMC: 3021209. DOI: 10.1128/CMR.00030-10. View

Dunn W, Broadhurst D, Brown M, Baker P, Redman C, Kenny L . Metabolic profiling of serum using Ultra Performance Liquid Chromatography and the LTQ-Orbitrap mass spectrometry system. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 871(2):288-98. DOI: 10.1016/j.jchromb.2008.03.021. View

Projan S . Why is big Pharma getting out of antibacterial drug discovery?. Curr Opin Microbiol. 2003; 6(5):427-30. DOI: 10.1016/j.mib.2003.08.003. View

Manetti F, Cona A, Angeli L, Mugnaini C, Raffi F, Capone C . Synthesis and biological evaluation of guanidino compounds endowed with subnanomolar affinity as competitive inhibitors of maize polyamine oxidase. J Med Chem. 2009; 52(15):4774-85. DOI: 10.1021/jm900371z. View

Tommasi R, Brown D, Walkup G, Manchester J, Miller A . ESKAPEing the labyrinth of antibacterial discovery. Nat Rev Drug Discov. 2015; 14(8):529-42. DOI: 10.1038/nrd4572. View

Gould I, Bal A . New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013; 4(2):185-91. PMC: 3654619. DOI: 10.4161/viru.22507. View

Piddock L . The crisis of no new antibiotics--what is the way forward?. Lancet Infect Dis. 2011; 12(3):249-53. DOI: 10.1016/S1473-3099(11)70316-4. View

Makarov A, Denisov E, Lange O, Horning S . Dynamic range of mass accuracy in LTQ Orbitrap hybrid mass spectrometer. J Am Soc Mass Spectrom. 2006; 17(7):977-982. DOI: 10.1016/j.jasms.2006.03.006. View

10.

Peterman S, Duczak Jr N, Kalgutkar A, Lame M, Soglia J . Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements. J Am Soc Mass Spectrom. 2006; 17(3):363-75. DOI: 10.1016/j.jasms.2005.11.014. View

11.

Maccari G, Sanfilippo S, De Luca F, Deodato D, Casian A, Dasso Lang M . Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity. Bioorg Med Chem Lett. 2014; 24(23):5525-9. DOI: 10.1016/j.bmcl.2014.09.081. View

12.

Haddad T, Kummerer K . Characterization of photo-transformation products of the antibiotic drug Ciprofloxacin with liquid chromatography-tandem mass spectrometry in combination with accurate mass determination using an LTQ-Orbitrap. Chemosphere. 2014; 115:40-6. DOI: 10.1016/j.chemosphere.2014.02.013. View

13.

Ventola C . The antibiotic resistance crisis: part 1: causes and threats. P T. 2015; 40(4):277-83. PMC: 4378521. View

14.

Bush K . Introduction to Antimicrobial therapeutics reviews: infectious diseases of current and emerging concern. Ann N Y Acad Sci. 2014; 1323:v-vi. DOI: 10.1111/nyas.12541. View

15.

Bartlett J, Gilbert D, Spellberg B . Seven ways to preserve the miracle of antibiotics. Clin Infect Dis. 2013; 56(10):1445-50. DOI: 10.1093/cid/cit070. View

16.

Boucher H, Talbot G, Benjamin Jr D, Bradley J, Guidos R, Jones R . 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56(12):1685-94. PMC: 3707426. DOI: 10.1093/cid/cit152. View

17.

Tally F, DeBruin M . Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 2000; 46(4):523-6. DOI: 10.1093/jac/46.4.523. View

18.

Fair R, Tor Y . Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014; 6:25-64. PMC: 4159373. DOI: 10.4137/PMC.S14459. View

19.

McKenna M . Antibiotic resistance: the last resort. Nature. 2013; 499(7459):394-6. DOI: 10.1038/499394a. View

20.

Fleeman R, Lavoi T, Santos R, Morales A, Nefzi A, Welmaker G . Combinatorial Libraries As a Tool for the Discovery of Novel, Broad-Spectrum Antibacterial Agents Targeting the ESKAPE Pathogens. J Med Chem. 2015; 58(8):3340-55. PMC: 8982266. DOI: 10.1021/jm501628s. View